FDA Approved: AMVUTTRA — Original Application (Alnylam Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved AMVUTTRA (vutrisiran) from Alnylam Pharmaceuticals for hereditary transthyretin-mediated amyloidosis with polyneuropathy. This represents a new…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy

Drugs mentioned

• AMVUTTRA (VUTRISIRAN)

Snippet

ORIG AP for AMVUTTRA (VUTRISIRAN)